疾病风险与GVHD生物标志物可分层预测HCT后复发与非复发死亡风险
本研究在多中心1604例异基因造血细胞移植患者中,检验MAGIC算法概率(MAP)能否识别复发风险高于严重GVHD和非复发死亡(NRM)风险的患者。HCT后28天未发生GVHD且MAP低的患者,复发风险(24%)明显高于严重GVHD(16%)和NRM(9%);高疾病风险指数者差异更明显(复发33%,NRM 9%)。
要点
- HCT后28天未发生GVHD且MAP低的患者,复发风险高于严重GVHD和NRM风险。
- 高疾病风险指数且MAP低的患者复发风险更高,是测试复发预防策略的合适人群。
- MAP可结合疾病风险对移植后患者进行复发与NRM风险分层。
核心结论
- HCT后28天未发生GVHD且MAP低的患者,其复发风险高于严重GVHD和NRM风险。
- 高疾病风险指数患者中这一差异更明显,此类患者适合测试增强GVL的复发预防策略。
研究设计与样本
- 多中心研究,总人群n=1604,分为历史队列(2006-2015年,n=702)和当前队列(2015-2017年,n=902)。
- 两个队列的NRM、复发和生存情况相似。
- 采用经验证的MAGIC算法概率(MAP),通过血清生物标志物预测无症状患者严重GVHD和NRM风险。
主要发现
- HCT后28天,75%的患者未发生GVHD。
- 未发生GVHD且MAP低的患者,复发风险为24%,严重GVHD为16%,NRM为9%。
- 高疾病风险指数患者中,复发风险为33%,NRM为9%。
临床怎么用
- 对HCT后28天未发生GVHD且MAP低的患者,可考虑其复发风险高于严重GVHD和NRM风险。
- 对高疾病风险指数且MAP低的患者,可评估其作为复发预防策略临床试验候选人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The graft-versus-leukemia (GVL) effect after allogeneic hematopoietic cell transplant (HCT) can prevent relapse but the risk of severe graft-versus-host disease (GVHD) leads to prolonged intensive immunosuppression and possible blunting of the GVL effect. Strategies to reduce immunosuppression in order to prevent relapse have been offset by increases in severe GVHD and nonrelapse mortality (NRM). We recently validated the MAGIC algorithm probability (MAP) that predicts the risk for severe GVHD and NRM in asymptomatic patients using serum biomarkers. In this study we tested whether the MAP could identify patients whose risk for relapse is higher than their risk for severe GVHD and NRM. The multicenter study population (n = 1604) was divided into two cohorts: historical (2006-2015, n = 702) and current (2015-2017, n = 902) with similar NRM, relapse, and survival. On day 28 post-HCT, patients who had not developed GVHD (75% of the population) and who possessed a low MAP were at much higher risk for relapse (24%) than severe GVHD and NRM (16 and 9%); this difference was even more pronounced in patients with a high disease risk index (relapse 33%, NRM 9%). Such patients are good candidates to test relapse prevention strategies that might enhance GVL.
引用
- Aziz MD, Shah J, Kapoor U, et al. Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant. Leukemia. 2020. PMID: 32020045. doi:10.1038/s41375-020-0726-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。